BR0110706A - Genes gagpol sintéticos e seus usos - Google Patents

Genes gagpol sintéticos e seus usos

Info

Publication number
BR0110706A
BR0110706A BR0110706-2A BR0110706A BR0110706A BR 0110706 A BR0110706 A BR 0110706A BR 0110706 A BR0110706 A BR 0110706A BR 0110706 A BR0110706 A BR 0110706A
Authority
BR
Brazil
Prior art keywords
gagpol genes
synthetic
genes
synthetic gagpol
generation
Prior art date
Application number
BR0110706-2A
Other languages
English (en)
Inventor
Ralf Wagner
Markus Graf
Ludwig Demil
Kurt Bieler
Original Assignee
Geneart Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8168767&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0110706(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Geneart Gmbh filed Critical Geneart Gmbh
Publication of BR0110706A publication Critical patent/BR0110706A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/1276—RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

"GENES GAGPOL SINTéTICOS E SEUS USOS". A presente invenção está relacionada com os genes gagpol e gag otimizados para alto nível de expressão via otimização de códon e os seus usos para a produção eficiente de partículas de vetor. A invenção também está relacionada com a produção de células e vacinas envelopadas com base nos genes gagpol e gag sintéticos.
BR0110706-2A 2000-05-18 2001-05-18 Genes gagpol sintéticos e seus usos BR0110706A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00110623A EP1156112B1 (en) 2000-05-18 2000-05-18 Synthetic gagpol genes and their uses
PCT/EP2001/005744 WO2001088141A2 (en) 2000-05-18 2001-05-18 Synthetic gagpol genes and their uses

Publications (1)

Publication Number Publication Date
BR0110706A true BR0110706A (pt) 2003-01-28

Family

ID=8168767

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0110706-2A BR0110706A (pt) 2000-05-18 2001-05-18 Genes gagpol sintéticos e seus usos

Country Status (10)

Country Link
US (3) US7378515B2 (pt)
EP (2) EP1156112B1 (pt)
CN (1) CN1429270A (pt)
AT (2) ATE318908T1 (pt)
AU (1) AU2001281781A1 (pt)
BR (1) BR0110706A (pt)
CA (1) CA2408433A1 (pt)
DE (2) DE60026199T2 (pt)
HK (1) HK1042319B (pt)
WO (1) WO2001088141A2 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004508064A (ja) * 2000-09-15 2004-03-18 メルク　エンド　カムパニー　インコーポレーテッド コドン最適化ｈｉｖ１−ｇａｇ、ｐｏｌ、ｎｅｆおよび修飾体を発現する増強された第１世代アデノウイルスワクチン
EP1201750A1 (en) * 2000-10-26 2002-05-02 Genopoietic Synthetic viruses and uses thereof
JP4601956B2 (ja) * 2001-09-20 2010-12-22 グラクソ グループ リミテッド Ｈｉｖ−ｇａｇのコドン最適化ｄｎａワクチン
DE10260805A1 (de) 2002-12-23 2004-07-22 Geneart Gmbh Verfahren und Vorrichtung zum Optimieren einer Nucleotidsequenz zur Expression eines Proteins
WO2004058166A2 (en) 2002-12-23 2004-07-15 Vical Incorporated Codon-optimized polynucleotide-based vaccines against human cytomegalovirus infection
US20050220816A1 (en) * 2004-03-31 2005-10-06 Advanced Bioscience Laboratories, Inc. Mutant viral nucleic acids and vaccine containing same
DE102004037611B4 (de) * 2004-08-03 2013-10-02 Geneart Ag Induzierbare Genexpression
CA2575490A1 (en) * 2004-08-03 2006-02-16 Frank Notka Method for modulating gene expression by altering the cpg content
ES2281252B1 (es) * 2005-07-27 2009-02-16 Consejo Superior De Investigaciones Cientificas Vectores recombinantes basados en el virus modificado de ankara (mva) como vacunas preventivas y terapeuticas contra el sida.
US8323891B2 (en) * 2008-08-01 2012-12-04 Claflin University miRNA triplex formations for the downregulation of viral replication
WO2011119920A2 (en) 2010-03-25 2011-09-29 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
ES2667425T3 (es) 2011-06-10 2018-05-10 Oregon Health & Science University Glucoproteínas y vectores recombinantes de CMV
EP2620446A1 (en) 2012-01-27 2013-07-31 Laboratorios Del Dr. Esteve, S.A. Immunogens for HIV vaccination
JP6224077B2 (ja) 2012-04-17 2017-11-01 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 改変された核酸を用いてポリペプチドを発現させるための方法
CN113924114A (zh) 2019-05-22 2022-01-11 吉利德科学公司 Tlr7调节化合物和hiv疫苗的组合
BR112021025806A2 (pt) 2019-06-28 2022-02-08 Hoffmann La Roche Métodos para produzir um anticorpo da subclasse igg1 humana cultivando uma célula cho e uso da remoção de sítios de splice de doador não pareados em uma parte de uma sequência de ácido nucleico de humano ou hamster
AU2020384323A1 (en) 2019-11-14 2022-06-02 Aelix Therapeutics, S.L. Dosage regimens for vaccines

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE9900343A (et) * 1997-02-07 2000-02-15 Merck & Co., Inc. Sünteetiline polünukleotiid, immuunvastuste tekitamise meetod, immunogeenne kompositsioon, anti-HIV immuunvastuste indutseerimise meetod, meetod antigeeni tekitava raku indutseerimiseks ja farmatseutiline kompositsioon
AU6139699A (en) * 1998-09-11 2000-04-03 Children's Medical Center Corporation Packaging cell lines for hiv-derived retroviral vector particles
EP1141314A2 (en) * 1998-12-31 2001-10-10 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof

Also Published As

Publication number Publication date
WO2001088141A3 (en) 2002-04-18
HK1042319A1 (en) 2002-08-09
HK1042319B (en) 2006-10-20
DE60026199T2 (de) 2006-11-23
US7378515B2 (en) 2008-05-27
US20130122585A1 (en) 2013-05-16
AU2001281781A1 (en) 2001-11-26
EP1156112B1 (en) 2006-03-01
US20070293448A1 (en) 2007-12-20
EP1282712B1 (en) 2006-07-19
DE60026199D1 (de) 2006-04-27
US20040152069A1 (en) 2004-08-05
DE60121572D1 (de) 2006-08-31
ATE318908T1 (de) 2006-03-15
EP1156112A1 (en) 2001-11-21
CA2408433A1 (en) 2001-11-22
WO2001088141A2 (en) 2001-11-22
CN1429270A (zh) 2003-07-09
US8287881B2 (en) 2012-10-16
ATE333503T1 (de) 2006-08-15
HK1053853A1 (en) 2003-11-07
DE60121572T2 (de) 2007-06-28
EP1282712A2 (en) 2003-02-12

Similar Documents

Publication Publication Date Title
AU2001281781A1 (en) Synthetic gagpol genes and their uses
ATE295895T1 (de) Genetischer impfstoff gegen den immunschwäche virus
HUP0301659A2 (hu) Kukorica cellulóz-szintetázok és alkalmazásuk
IL143326A0 (en) Method of cloning porcine animals
WO2003000038A3 (en) Compositions and methods for modulating plant development
GB2405406B (en) Viral vectors
SI1644484T1 (sl) Avtologne samo-toleranco inducirajoče celice monocitnega izvora in njihova uporaba v farmacevtskihpripravah
ATE361366T1 (de) Aus bacillus stammende transglutaminase
CY1118443T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις
YU9403A (sh) Anti-dualna antitela integrina, kompozicije, postupci i primene
MEP44408A (en) Anti-il-12 antibodies, compositions, methods and uses
DE69839215D1 (de) Dendritische zellhybride
DK580583A (da) Derivater af cis,endo-2-azabicyclo-(5.3.0)-decan-3-carboxylsyre, fremgangsmaade til deres fremstilling samt midler indeholdende disse og deres anvendelse
IL143670A0 (en) Methods for the expression of active protein-immunoglobulin fusions, active protein-immunoglobulin fusions obtained thereby and pharmaceutical compositions containing the same
AU2003275612A1 (en) Defructosylation method
DE60042816D1 (de) T-helferzellen-epitope
PL367306A1 (pl) Szczepionki na bazie autologicznych komórek T i sposoby ich otrzymywania
WO2002014526A3 (en) Replication competent aav helper functions
DE60135770D1 (de) Identifizierung und charakterisierung einer anthocyaninmutante (ant1) in tomate
BR9803232A (pt) Vaicna de neospora.
DK0871612T3 (da) Kondenserede isoindoloner som proteinkinase C-inhibitorer
ATE494377T1 (de) Vakzine gegen ipnv die aus hefezellen isoliert werden
EP1407007A4 (en) ATTENUATED CIRCOVIRUS
DE69232858D1 (de) Herpesvirus-partikel zubereitung und vakzine
IL79606A0 (en) Thiono-and dithionophosphonic acid esters,their preparation and their use as pesticides

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: GENEART AG (DE)

Free format text: ALTERADO DE: GENEART GMBH

B25G Requested change of headquarter approved

Owner name: GENEART AG (DE)

Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 020070142696/RJ DE 10/10/2007.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]